The Frontier Psychiatrists

The Frontier Psychiatrists

Share this post

The Frontier Psychiatrists
The Frontier Psychiatrists
Saving MDMA VII: This isn't The First Drug to Have Problems Getting Approved

Saving MDMA VII: This isn't The First Drug to Have Problems Getting Approved

A bedtime story about another first-in-class drug.

Owen Scott Muir, M.D, DFAACAP's avatar
Owen Scott Muir, M.D, DFAACAP
Jun 26, 2024
∙ Paid
9

Share this post

The Frontier Psychiatrists
The Frontier Psychiatrists
Saving MDMA VII: This isn't The First Drug to Have Problems Getting Approved
3
3
Share

The Frontier Psychiatrists is a daily enough health-themed newsletter. Recently, I've done quite a bit of writing around the FDA approval process for the Lykos Theraputics Breakthrough Submission of MDMA-AT. That stands for MDMA-assisted therapy. The pretense is that this breakthrough treatment is a combination of an old off-patent drug, MDMA, and manualized Psychotherapy. I've already written about how I think the therapeutic component of this is not good. Like others, I have written about some of the very serious problems in the clinical trials from both an ethics and an FDA perspective. Here are those prior articles—subscribe! Some are behind a paywall now—you snooze, am I right?

The “Saving MDMA” Series!

Can MDMA-AT Be Saved, Part I

Can MDMA-AT Be Saved, Part II

Should MDMA-AT Be Saved, Part III

Saving MDMA from AT: Part IV

Bad Touch!: MDMA Part V

Saving MDMA (and other psychedelic therapies), Part VI

To put my dime down, I don't think MDMA-AT will be approved by the FDA when it …

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 The Frontier Psychiatrists
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share